Pregnancy and Reproductive Health in ME/CFS
1 Schacterle & Komaroff 2004 — Pregnancy Outcomes Before and After CFS Onset
(Schacterle and Komaroff 2004)
Full Citation:: Schacterle RS, Komaroff AL. “A Comparison of Pregnancies That Occur Before and After the Onset of Chronic Fatigue Syndrome.” Archives of Internal Medicine. 2004;164(4):401–404. DOI:: 10.1001/archinte.164.4.401 PMID:: 14980991 Study Design:: Retrospective questionnaire survey; n=86 women; 252 pregnancies compared (171 before CFS onset, 75 after onset, 43 live births after onset); patients used as own controls. Key Findings::
- Spontaneous abortion rate 30% in pregnancies after CFS onset vs 8% before onset (statistically significant)
- Offspring developmental delays or learning disabilities: 21% (born after onset) vs 8% (born before onset)
- Symptom change during pregnancy: 41% no change, 30% improved, 29% worsened
- Most maternal complications (pre-eclampsia, gestational diabetes, mode of delivery) did not differ significantly by CFS statusConclusion:: The only quantitative primary study of pregnancy outcomes in CFS with an internal control design. Raises important signals for spontaneous abortion and offspring neurodevelopment that remain unreplicated. The within-person design (same women before and after CFS onset) partially controls for individual baseline risk, but cannot control for maternal age at time of pregnancy. Limitations:: Retrospective self-report with recall bias risk; no external age-matched control group; maternal age confound (post-onset pregnancies occur later in life); small post-onset live birth sample (n=43); published 2004 using Fukuda 1994 CFS criteria; no replication study published as of 2025. Certainty:: 0.42
2 Slack et al. 2023 — ME/CFS and Pregnancy: Mixed-Methods Systematic Review
Full Citation:: Slack E, Pears KA, Rankin J, Newton JL, Pearce M. “Identifying, synthesising and appraising existing evidence relating to myalgic encephalomyelitis/chronic fatigue syndrome and pregnancy: a mixed-methods systematic review.” BMJ Open. 2023;13(10):e070366. DOI:: 10.1136/bmjopen-2022-070366 PMID:: 37798026 PMCID:: PMC10565252 Study Design:: Mixed-methods systematic review (convergent segregated design); 16 included studies (4 quantitative, 11 qualitative, 1 mixed-methods) from 3,675 initially screened articles. Key Findings::
- Evidence on ME/CFS and pregnancy is highly limited and findings are inconclusive
- Pregnancy effects on ME/CFS symptoms are individual and variable: different quantitative studies report 29--42% worsening, 27--30% improvement, and up to 41% no change
- Qualitative evidence emphasizes that experiences vary not only between people but between pregnancies in the same person
- Postpartum relapse (3--6 months after delivery) reported clinically; hypothesised mechanism: physiological reduction in blood volume plus sleep disruption
- Spontaneous abortion signal from Schacterle 2004 (30% vs 8%) has not been independently replicated
- Difficulty making parenthood decisions is a significant reported burden for people with ME/CFSConclusion:: The most comprehensive synthesis of ME/CFS and pregnancy evidence to date. Confirms the extreme evidence gap: only 5 of 16 included studies are peer-reviewed, most have no control groups, and none are prospective with adequate power. Calls urgently for high-quality prospective controlled studies. Limitations:: Very limited primary evidence base to synthesise; no studies adjusted for maternal age confound; lack of standardized ME/CFS diagnostic criteria across studies; severely affected individuals under-represented in all studies. Certainty:: 0.52
3 Thomas et al. 2022 — Sex Differences and Neuroendocrinology in ME/CFS
Full Citation:: Thomas N, Gurvich C, Huang K, Gooley PR, Armstrong CW. “The underlying sex differences in neuroendocrine adaptations relevant to Myalgic Encephalomyelitis Chronic Fatigue Syndrome.” Frontiers in Neuroendocrinology. 2022;66:100995. DOI:: 10.1016/j.yfrne.2022.100995 PMID:: 35421511 Study Design:: Narrative review. Key Findings::
- ME/CFS shows a 3:1 female predominance; sex dimorphism in prevalence, clinical phenotypes, and etiological triggers
- Female reproductive life events correlate with ME/CFS onset and symptom fluctuation: menarche, menstrual cycle phase, pregnancy, postpartum period, perimenopause
- Gonadal (estrogen, progesterone), adrenal (cortisol), and renal (aldosterone) neuroendocrine systems all implicated, each with established sex differences
- Estrogen is the most studied sex steroid in ME/CFS; menstrual cycle phase influences fatigue, pain, and cognitive function in ME/CFS patients
- Pregnancy is reported as a trigger for ME/CFS onset in 3--10% of cases; postpartum period is a recognized vulnerability windowConclusion:: Provides a theoretical framework for understanding why ME/CFS disproportionately affects women and why reproductive events modulate symptom onset and severity. The neuroendocrine mechanisms identified (especially HPA and HPG axis interactions) offer testable targets for future research. Relevant for interpreting the Schacterle 2004 pregnancy findings within a biological context. Limitations:: Narrative review without systematic search; no primary data; mechanistic claims require further experimental validation. Certainty:: 0.55
4 Allen 2008 — CFS Implications for Women During the Childbearing Years
Full Citation:: Allen PR. “Chronic fatigue syndrome: implications for women and their health care providers during the childbearing years.” Journal of Midwifery & Women’s Health. 2008;53(4):289–301. DOI:: 10.1016/j.jmwh.2007.12.001 PMID:: 18586181 Study Design:: Narrative review with clinical practice guidelines; not primary research. Key Findings::
- Approximately 4 million people in the US have CFS; women predominantly affected
- Notes severe scarcity of scientific literature on the reproductive experience of women with CFS at time of publication
- Provides guidance for pregnancy, labor and birth, lactation, and postpartum care in the context of CFS
- Identifies that misperceptions among healthcare providers create significant burden for patientsConclusion:: Clinically useful framework for midwifery and obstetric providers caring for women with CFS during childbearing. The evidence gap it identifies in 2008 has only been partially addressed by the 2023 Slack systematic review. Limitations:: Narrative review; no systematic search; guidance not evidence-based in the strict sense; pre-2011 diagnostic criteria; not updated since publication. Certainty:: 0.38
5 Compton et al. 2025 — Endometriosis and ME/CFS: Systematic Review and Meta-Analysis
Full Citation:: Compton S, Alkabalan R, Cadet J, Mastali A, Ramdass PVK. “Endometriosis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review and Meta-Analysis.” Diagnostics. 2025;15(18):2332. DOI:: 10.3390/diagnostics15182332 PMID:: 41008704 Study Design:: Systematic review and meta-analysis (PRISMA 2020); 13 studies included (8 cross-sectional, 2 case-control, 3 cohort); study sample sizes ranged from 84 to 134,805 participants; publications 2002–2024. Key Findings::
- Women with endometriosis have 2.79-fold higher odds (95% CI: 2.00--3.89) of developing ME/CFS compared to controls
- Pooled OR for ME/CFS--endometriosis association: 2.52 (95% CI: 2.45--2.60)
- ME/CFS prevalence in endometriosis patient populations: 17% (95% CI: 6--41%)
- Endometriosis prevalence in ME/CFS patient populations: 13% (95% CI: 5--31%)
- Minimal heterogeneity for association studies (I^2^ = 0.0%); extreme heterogeneity for prevalence estimates (I^2^ >98%)Conclusion:: First meta-analysis to quantify the ME/CFS–endometriosis comorbidity association. The 2.79-fold odds ratio is clinically meaningful and aligns with the broader pattern of ME/CFS co-occurring with conditions driven by immune dysregulation and chronic inflammation. Shared mechanisms may include neuroinflammation, HPA axis dysregulation, and altered immune tolerance. Relevant to gynecological assessment in ME/CFS patients. Limitations:: Predominantly cross-sectional designs preclude causal inference; 54% of studies used self-reported endometriosis diagnosis (not laparoscopic confirmation); extreme prevalence heterogeneity (I2 >98%) cautions against pooled prevalence estimates; US-centric sample (11/13 studies); only 23% of studies used standardized ME/CFS diagnostic criteria. Certainty:: 0.58
6 Pollack et al. 2023 — Female Reproductive Health in Long COVID and ME/CFS
Full Citation:: Pollack B, von Saltza E, McCorkell L, Santos L, Hultman A, Cohen AK, Soares L. “Female reproductive health impacts of Long COVID and associated illnesses including ME/CFS, POTS, and connective tissue disorders: a literature review.” Frontiers in Rehabilitation Sciences. 2023;4:1122673. DOI:: 10.3389/fresc.2023.1122673 PMID:: 37234076 Study Design:: Literature review; not primary research. Key Findings::
- Long COVID, ME/CFS, POTS, and EDS disproportionately affect premenopausal women (70--80% female in affected populations)
- Long COVID may cause menstrual cycle disruptions, gonadal dysfunction, premature ovarian insufficiency, and adverse pregnancy outcomes
- Associated conditions show elevated rates of dysmenorrhea, amenorrhea, infertility, and endometriosis
- Critical knowledge gaps: how sex hormones, menstrual cycle phase, pregnancy, and menopause influence symptom progression in these conditions
- Historical inequities in medical research for predominantly female patient populations have contributed to the evidence gapConclusion:: Provides a broad overview of the intersection of post-infectious illness and female reproductive health. Useful for contextualising ME/CFS pregnancy findings within the wider Long COVID/POTS/EDS cluster. Identifies the same evidence gap as Slack 2023 but from a broader infection-associated illness perspective. Limitations:: Literature review without systematic search; Long COVID literature is very recent and rapidly evolving; conflates several distinct conditions; no primary data; some claims extrapolated from associated conditions rather than ME/CFS specifically. Certainty:: 0.45